Sung Ji Nam
Stock Analyst at Scotiabank
(2.17)
# 2,867
Out of 4,944 analysts
83
Total ratings
44.12%
Success rate
-4.92%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $58.57 | +2.44% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $54.71 | +37.09% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $209.14 | +31.49% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $484.79 | +21.70% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $101.11 | +23.63% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $19.41 | +106.08% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $3 → $2 | $0.38 | +421.51% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.87 | +2.21% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $3.24 | +23.46% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.28 | +56.25% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $44.91 | +62.55% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $13.00 | -7.69% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $296.83 | +51.60% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $28.65 | +116.40% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $30.68 | +43.42% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $12.13 | +188.54% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $4.88 | +22.95% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $21.78 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $58.57
Upside: +2.44%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $54.71
Upside: +37.09%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $209.14
Upside: +31.49%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $484.79
Upside: +21.70%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $101.11
Upside: +23.63%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $19.41
Upside: +106.08%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $3 → $2
Current: $0.38
Upside: +421.51%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.87
Upside: +2.21%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $3.24
Upside: +23.46%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.28
Upside: +56.25%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $44.91
Upside: +62.55%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $13.00
Upside: -7.69%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $296.83
Upside: +51.60%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $28.65
Upside: +116.40%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $30.68
Upside: +43.42%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $12.13
Upside: +188.54%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $4.88
Upside: +22.95%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $21.78
Upside: -